243 related articles for article (PubMed ID: 17377527)
1. Challenges in the discovery and development of new agents for the treatment of obesity.
Staten MA
Clin Pharmacol Ther; 2007 May; 81(5):753-5. PubMed ID: 17377527
[TBL] [Abstract][Full Text] [Related]
2. Obesity pharmacotherapy from a regulatory perspective: overview and key challenges.
Hutchinson NI; Ryder SW
Clin Pharmacol Ther; 2007 May; 81(5):756-60. PubMed ID: 17392723
[TBL] [Abstract][Full Text] [Related]
3. The success of bariatric surgery as treatment of type 2 diabetes should be a call to revitalize anti-obesity drug discovery and development.
Opgenorth TJ
Curr Opin Investig Drugs; 2008 Apr; 9(4):355-6. PubMed ID: 18393101
[No Abstract] [Full Text] [Related]
4. [Drug therapy of obesity--from bitter experiences to future possibilities].
Rössner S
Lakartidningen; 2000 Apr; 97(14):1726-8. PubMed ID: 10815399
[No Abstract] [Full Text] [Related]
5. New drug targets for the treatment of obesity.
Powell AG; Apovian CM; Aronne LJ
Clin Pharmacol Ther; 2011 Jul; 90(1):40-51. PubMed ID: 21654742
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic therapy for obesity.
Udall JN; Licciardi DM; Svec F
J La State Med Soc; 2005 Jan; 157 Spec No 1():S56-64. PubMed ID: 15751911
[TBL] [Abstract][Full Text] [Related]
7. Obesity, body image and diet drugs: 100 years of change.
Scheindlin S
Mol Interv; 2008 Apr; 8(2):64-9. PubMed ID: 18403649
[No Abstract] [Full Text] [Related]
8. Medical therapy for obesity--current status and future hopes.
Bray GA
Med Clin North Am; 2007 Nov; 91(6):1225-53, xi. PubMed ID: 17964918
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines.
Correia ML; Haynes WG
Expert Opin Emerg Drugs; 2005 Aug; 10(3):643-60. PubMed ID: 16083333
[TBL] [Abstract][Full Text] [Related]
10. Dinitrophenol and obesity: an early twentieth-century regulatory dilemma.
Colman E
Regul Toxicol Pharmacol; 2007 Jul; 48(2):115-7. PubMed ID: 17475379
[TBL] [Abstract][Full Text] [Related]
11. New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?
Kennett GA; Clifton PG
Pharmacol Biochem Behav; 2010 Nov; 97(1):63-83. PubMed ID: 20688100
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical treatment of obesity.
Blackburn GL; Miller D; Chan S
Nurs Clin North Am; 1997 Dec; 32(4):831-48. PubMed ID: 9386228
[TBL] [Abstract][Full Text] [Related]
13. The obesity pipeline: current strategies in the development of anti-obesity drugs.
Cooke D; Bloom S
Nat Rev Drug Discov; 2006 Nov; 5(11):919-31. PubMed ID: 17080028
[TBL] [Abstract][Full Text] [Related]
14. Medications for weight reduction.
Bray GA
Endocrinol Metab Clin North Am; 2008 Dec; 37(4):923-42. PubMed ID: 19026940
[TBL] [Abstract][Full Text] [Related]
15. Companies throw their weight behind new antiobesity drugs.
Cahoon L
Nat Med; 2010 Feb; 16(2):136. PubMed ID: 20134442
[No Abstract] [Full Text] [Related]
16. A critical review of the cannabinoid receptor as a drug target for obesity management.
Akbas F; Gasteyger C; Sjödin A; Astrup A; Larsen TM
Obes Rev; 2009 Jan; 10(1):58-67. PubMed ID: 18721231
[TBL] [Abstract][Full Text] [Related]
17. What is the prognosis for new centrally-acting anti-obesity drugs?
Heal DJ; Gosden J; Smith SL
Neuropharmacology; 2012 Jul; 63(1):132-46. PubMed ID: 22313529
[TBL] [Abstract][Full Text] [Related]
18. [Novel anti-obesity drugs].
Tripp B; Ludvik B
Acta Med Austriaca; 2004; 31(4):133-8. PubMed ID: 15732249
[TBL] [Abstract][Full Text] [Related]
19. Well-being of obese individuals: therapeutic perspectives.
Chaput JP; Tremblay A
Future Med Chem; 2010 Dec; 2(12):1729-33. PubMed ID: 21428796
[TBL] [Abstract][Full Text] [Related]
20. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Hagmann WK
Arch Pharm (Weinheim); 2008 Jul; 341(7):405-11. PubMed ID: 18574849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
